Chronic myeloid leukaemia vaccine

Drug Profile

Chronic myeloid leukaemia vaccine

Alternative Names: Ablvax; Chronic myelogenous leukaemia vaccine; CMLVAX 100; CMLVAX 500; Multivalent BCR-ABL oncogene product fusion peptide vaccine; VAX 100

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Breakthrough Therapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 12 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the adverse events and Cancer therapeutic trials section ,
  • 04 Mar 2005 The vaccine has been licensed to Breakthrough Therapeutics
  • 04 Mar 2005 Data from a media release have been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top